[The use of diksafen for curing the neurotoxic reactions of cancer patients undergoing radiation and chemotherapy].

Abstract

The paper discusses a clinical trial of a newly developed Soviet preparation--dixaphen which was administered to 40 patients who had received radiation and chemotherapy for Hodgkin's disease and tumors at other sites. A single intramuscular injection of 1.0 ml was found to abort emesis in 80-90% and asthenic syndrome--in 60-75%. The drug was well tolerated; it is recommended for treatment of malignant tumors.

• Authors: V I Legeza, L I Korytova, B M Rakhmilevich, A I Rambovskiĭ
• Journal: Voprosy onkologii (Vopr Onkol) Vol. 38 Issue 2 Pg. 148-53 ( 1992) ISSN: 0507-3758 [Print] Russia (Federation)
• Vernacular Title: Primenenie diksafena dlia kupirovaniia neĭrotoksicheskikh reaktsiĭ u onkologicheskikh bol'nykh, podvergaiushchikhsia luchevoĭ i khimioterapii.
• PMID: 1300698 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antiemetics
• Benzamides
• Drug Combinations
• dixaphen
• Caffeine
• dimetpramid
• Ephedrine

Topics

• Adolescent
• Adult
• Antiemetics (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Asthenia (drug therapy, etiology)
• Benzamides (therapeutic use)
• Caffeine (therapeutic use)
• Combined Modality Therapy
• Drug Combinations
• Drug Evaluation
• Ephedrine (therapeutic use)
• Gastrointestinal Diseases (drug therapy, etiology)
• Humans
• Middle Aged
• Neoplasms (complications, drug therapy, radiotherapy)
• Nervous System (drug effects, radiation effects)
• Radiotherapy (adverse effects)